154 related articles for article (PubMed ID: 36621759)
21. Possible value of antifibrotic drugs in patients with progressive fibrosing non-IPF interstitial lung diseases.
Torrisi SE; Kahn N; Wälscher J; Sarmand N; Polke M; Lars K; Eichinger M; Heussel CP; Palmucci S; Sambataro FM; Sambataro G; Sambataro D; Vancheri C; Kreuter M
BMC Pulm Med; 2019 Nov; 19(1):213. PubMed ID: 31718637
[TBL] [Abstract][Full Text] [Related]
22. Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial.
Behr J; Prasse A; Kreuter M; Johow J; Rabe KF; Bonella F; Bonnet R; Grohe C; Held M; Wilkens H; Hammerl P; Koschel D; Blaas S; Wirtz H; Ficker JH; Neumeister W; Schönfeld N; Claussen M; Kneidinger N; Frankenberger M; Hummler S; Kahn N; Tello S; Freise J; Welte T; Neuser P; Günther A;
Lancet Respir Med; 2021 May; 9(5):476-486. PubMed ID: 33798455
[TBL] [Abstract][Full Text] [Related]
23. Interstitial Lung Disease in the Elderly.
Patterson KC; Shah RJ; Porteous MK; Christie JD; D'Errico CA; Chadwick M; Triano MJ; Deshpande C; Rossman MD; Litzky LA; Kreider M; Miller WT
Chest; 2017 Apr; 151(4):838-844. PubMed ID: 27865876
[TBL] [Abstract][Full Text] [Related]
24. Computed Tomography Honeycombing Identifies a Progressive Fibrotic Phenotype with Increased Mortality across Diverse Interstitial Lung Diseases.
Adegunsoye A; Oldham JM; Bellam SK; Montner S; Churpek MM; Noth I; Vij R; Strek ME; Chung JH
Ann Am Thorac Soc; 2019 May; 16(5):580-588. PubMed ID: 30653927
[No Abstract] [Full Text] [Related]
25. Association between immunosuppressive therapy and course of mild interstitial lung disease in systemic sclerosis.
Hoa S; Bernatsky S; Steele RJ; Baron M; Hudson M;
Rheumatology (Oxford); 2020 May; 59(5):1108-1117. PubMed ID: 31535689
[TBL] [Abstract][Full Text] [Related]
26. Care patterns of patients with chronic fibrosing interstitial lung disease (ILD) with a progressive phenotype.
Nili M; Singer D; Hanna M
BMC Pulm Med; 2022 Apr; 22(1):153. PubMed ID: 35459138
[TBL] [Abstract][Full Text] [Related]
27. Factors for progressive pulmonary fibrosis in connective tissue disease-related interstitial lung disease.
Kim K; Lee J; Jo YS
Ther Adv Respir Dis; 2023; 17():17534666231212301. PubMed ID: 37991015
[TBL] [Abstract][Full Text] [Related]
28. Cost drivers in the pharmacological treatment of interstitial lung disease.
Maqhuzu PN; Kreuter M; Bahmer T; Kahn N; Claussen M; Holle R; Schwarzkopf L
Respir Res; 2021 Aug; 22(1):218. PubMed ID: 34344376
[TBL] [Abstract][Full Text] [Related]
29. Causes of acute respiratory hospitalizations predict survival in fibrosing interstitial lung diseases.
Salonen J; Vähänikkilä H; Purokivi M; Kaarteenaho R
PLoS One; 2020; 15(11):e0242860. PubMed ID: 33253258
[TBL] [Abstract][Full Text] [Related]
30. Treatment Outcomes for Rheumatoid Arthritis-Associated Interstitial Lung Disease: A Real-World, Multisite Study of the Impact of Immunosuppression on Pulmonary Function Trajectory.
Matson SM; Baqir M; Moua T; Marll M; Kent J; Iannazzo NS; Boente RD; Donatelli JM; Dai J; Diaz FJ; Demoruelle MK; Hamblin MB; Mathai SK; Ryu JH; Pope K; Walker CM; Lee JS
Chest; 2023 Apr; 163(4):861-869. PubMed ID: 36470416
[TBL] [Abstract][Full Text] [Related]
31. Factors influencing long-term outcomes in fibrotic interstitial lung disease (F-ILD) diagnosed through multidisciplinary discussion (MDD): a prospective cohort study.
Liao YW; Liu MC; Wu YC; Hsu CY; Huang WN; Chen YH; Fu PK
Eur J Med Res; 2024 Jan; 29(1):91. PubMed ID: 38291459
[TBL] [Abstract][Full Text] [Related]
32. Effectiveness and tolerability of antifibrotics in rheumatoid arthritis-associated interstitial lung disease.
Juge PA; Hayashi K; McDermott GC; Vanni KMM; Kowalski E; Qian G; Bade K; Saavedra A; Dieudé P; Dellaripa PF; Doyle TJ; Sparks JA
Semin Arthritis Rheum; 2024 Feb; 64():152312. PubMed ID: 38056314
[TBL] [Abstract][Full Text] [Related]
33. Acute exacerbations of fibrosing interstitial lung disease associated with connective tissue diseases: a population-based study.
Cao M; Sheng J; Qiu X; Wang D; Wang D; Wang Y; Xiao Y; Cai H
BMC Pulm Med; 2019 Nov; 19(1):215. PubMed ID: 31727051
[TBL] [Abstract][Full Text] [Related]
34. Integration and Application of Radiologic Patterns From Clinical Practice Guidelines on Idiopathic Pulmonary Fibrosis and Fibrotic Hypersensitivity Pneumonitis.
Marinescu DC; Hague CJ; Muller NL; Murphy D; Churg A; Wright JL; Al-Arnawoot A; Bilawich AM; Bourgouin P; Cox G; Durand C; Elliot T; Ellis J; Fisher JH; Fladeland D; Grant-Orser A; Goobie GC; Guenther Z; Haider E; Hambly N; Huynh J; Johannson KA; Karjala G; Khalil N; Kolb M; Leipsic J; Lok S; MacIsaac S; McInnis M; Manganas H; Marcoux V; Mayo J; Morisset J; Scallan C; Sedlic T; Shapera S; Sun K; Tan V; Wong AW; Zheng B; Ryerson CJ
Chest; 2023 Dec; 164(6):1466-1475. PubMed ID: 37541339
[TBL] [Abstract][Full Text] [Related]
35. Characteristics and Prevalence of Domestic and Occupational Inhalational Exposures Across Interstitial Lung Diseases.
Lee CT; Adegunsoye A; Chung JH; Ventura IB; Jablonski R; Montner S; Vij R; Hines SE; Strek ME
Chest; 2021 Jul; 160(1):209-218. PubMed ID: 33621598
[TBL] [Abstract][Full Text] [Related]
36. Interstitial Lung Disease in India. Results of a Prospective Registry.
Singh S; Collins BF; Sharma BB; Joshi JM; Talwar D; Katiyar S; Singh N; Ho L; Samaria JK; Bhattacharya P; Gupta R; Chaudhari S; Singh T; Moond V; Pipavath S; Ahuja J; Chetambath R; Ghoshal AG; Jain NK; Devi HJ; Kant S; Koul P; Dhar R; Swarnakar R; Sharma SK; Roy DJ; Sarmah KR; Jankharia B; Schmidt R; Katiyar SK; Jindal A; Mangal DK; Singh V; Raghu G
Am J Respir Crit Care Med; 2017 Mar; 195(6):801-813. PubMed ID: 27684041
[TBL] [Abstract][Full Text] [Related]
37. Local and Systemic Concentrations of Pattern Recognition Receptors of the Lectin Pathway of Complement in a Cohort of Patients With Interstitial Lung Diseases.
Vogt S; Trendelenburg M; Tamm M; Stolz D; Hostettler KE; Osthoff M
Front Immunol; 2020; 11():562564. PubMed ID: 33101280
[TBL] [Abstract][Full Text] [Related]
38. Review series: Aspects of interstitial lung disease: connective tissue disease-associated interstitial lung disease: how does it differ from IPF? How should the clinical approach differ?
de Lauretis A; Veeraraghavan S; Renzoni E
Chron Respir Dis; 2011; 8(1):53-82. PubMed ID: 21339375
[TBL] [Abstract][Full Text] [Related]
39. Sex and gender in interstitial lung diseases.
Kawano-Dourado L; Glassberg MK; Assayag D; Borie R; Johannson KA
Eur Respir Rev; 2021 Dec; 30(162):. PubMed ID: 34789464
[TBL] [Abstract][Full Text] [Related]
40. Baseline characteristics of systemic sclerosis patients with restrictive lung disease in a multi-center US-based longitudinal registry.
Castelino FV; VanBuren JM; Startup E; Assassi S; Bernstein EJ; Chung L; Correia C; Evnin LB; Frech TM; Gordon JK; Hant FN; Hummers LK; Khanna D; Sandorfi N; Shah AA; Shanmugam VK; Steen V
Int J Rheum Dis; 2022 Feb; 25(2):163-174. PubMed ID: 34841681
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
